Table 1 Demographic and disease characteristics of the study sample
Variable | Frequency (%) | Mean (SD) |
|---|---|---|
Age | Â | 40.3 (15.3) |
Age at SLE diagnosis | Â | 28.3 (12.1) |
Constitutional symptoms | 40 (63.5) | Â |
Organ involvement | Â | Â |
 Kidney | 19 (30.2) |  |
 Eye | 10 (15.9) |  |
 Heart | 36 (57.1) |  |
 Mucocutaneous | 53 (84.1) |  |
 Joints | 52 (82.5) |  |
 Hematological | 53 (84.1) |  |
 Vascular | 40 (63.5) |  |
 Gastrointestinal | 3 (4.8) |  |
 Pulmonary | 20 (31.7) |  |
 Neuropsychiatry | 9 (14.3) |  |
SLEDAI | Â | 7.6 (8.9) |
 Osteoporosis | 9 (14.3) |  |
 Osteopenia | 17 (27.0) |  |
Treatment | Â | Â |
 Glucocorticoids | 46 (73.0) |  |
 Mycophenolate | 24 (38.1) |  |
 Hydroxychloroquine | 50 (79.4) |  |
 Tacrolimus | 7 (11.1) |  |
 Azathioprine | 22 (34.9) |  |
 Methotrexate | 1 (1.6) |  |
 Leflunomide | 1 (1.6) |  |
 Cyclosporine | 1 (1.6) |  |
Laboratory results | Â | Â |
 ESR |  | 35.4 (25.7) |
 CRP |  | 6.5 (10.5) |
 Creatinine |  | 0.82 (0.39) |
 Lymphocytes |  | 1.8 (0.93) |
 Neutrophils |  | 3.9 (2.5) |
 Platelets |  | 2269.3 (88.8) |
 Hemoglobin |  | 11.8 (1.6) |
 NLR |  | 2.6 (2.4) |
 PLR |  | 180.7 (111.6) |
 Ds-DNA | 25 (39.7) |  |
 Low C3 | 16 (25.4) |  |
 Low C4 | 8 (12.7) |  |